Shanghai Pharmaceuticals Holding (02607): The isopropamide hydrochloride injection from Shanghai Pharmaceuticals Hefeng has passed the consistency evaluation of generic drugs.

Shanghai Pharmaceuticals Holding (02607) announced that its subsidiary Shanghai Hefeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Hefeng") has recently received the "Notice of Approval for Drug Supplement Application" (Notice No.: 2026B05365) issued by the National Medical Products Administration for isopropamide hydrochloride injection, which has passed the consistency evaluation for generic drugs. The indications for isopropamide hydrochloride injection are: (1) Allergies of the skin and mucous membranes: suitable for long-term and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, urticaria, angioedema, allergic reactions to blood or plasma products, and dermatographism. (2) Motion sickness: prevention and treatment of car sickness, seasickness, and air sickness. (3) Adjunctive treatment before and after anesthesia and surgery, including sedation, hypnosis, analgesia, and antiemetic effects. (4) Prevention and treatment of radiation sickness or drug-induced nausea and vomiting. According to relevant national policies, drugs that pass consistency evaluation will receive greater support in areas such as medical insurance payments and procurement by medical institutions. Therefore, the successful consistency evaluation of Hefengs isopropamide hydrochloride injection is beneficial for expanding the market share of this drug, enhancing its market competitiveness, and accumulating valuable experience for the company in conducting consistency evaluations for subsequent products.